C-PNE4Antoxis
cell-targeted antioxidants, mitochondrial dysfunction, redox platform
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PNE4
C-PNE4C-PNE4cell-targeted antioxidants, mitochondrial dysfunction, redox platform
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Antoxis cell-targeted antioxidants, mitochondrial dysfunction, redox platform
Antoxis is a biotechnology company designing and synthesizing novel cell-targeted antioxidants to limit free radical damage in clinical conditions with high unmet need. Its focus includes diseases of ageing such as diabetes, Parkinson's and Alzheimer's, as well as stem cell applications. The company has developed patented compound libraries based on plant antioxidant structure-activity relationships and is advancing pre-clinical programs with Pharma, the NHS and academic partners.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Antoxis — Early mechanism · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic